ライフサイエンスコーパス: healthy control subject

1 SH vs simple steatosis; P < .001 for NASH vs healthy control subjects).

2 d, moderate, and severe asthma and nonatopic healthy control subjects.

3 els for total cell-free circulating RNA from healthy control subjects.

4 complexity were analyzed and compared to 26 healthy control subjects.

5 ned from patients with GPP, PPP, or AGEP and healthy control subjects.

6 asthmatic patients with more eosinophils and healthy control subjects.

7 patients with ET and 18 age- and sex-matched healthy control subjects.

8 the opposite was observed in abstainers and healthy control subjects.

9 surements in patients with heart failure and healthy control subjects.

10 ith first-episode psychosis as compared with healthy control subjects.

11 man serum samples from lymphoma patients and healthy control subjects.

12 l caudate of patients with FEP compared with healthy control subjects.

13 ion in steroid-free patients with asthma and healthy control subjects.

14 al valve surgery and 13 age- and sex-matched healthy control subjects.

15 were 7,048 leprosy patients and 14,398 were healthy control subjects.

16 aries derived from 11 MG patients and paired healthy control subjects.

17 pus erythematosus without past NPSLE, and 19 healthy control subjects.

18 hronic schizophrenia patients and 26 matched healthy control subjects.

19 ) levels in asthmatic patients compared with healthy control subjects.

20 l Center and included 31 BDD, 39 MDD, and 36 healthy control subjects.

21 F before chest computed tomography and in 72 healthy control subjects.

22 acteria and less Bacteroidetes compared with healthy control subjects.

23 atients with Alzheimer's disease relative to healthy control subjects.

24 tivity in MDD, and by sparse connectivity in healthy control subjects.

25 s were compared with those in 30 age-matched healthy control subjects.

26 of patients with CVID compared with those of healthy control subjects.

27 nd ventilation were lower (P < 0.05) than in healthy control subjects.

28 re compared with 55 patients with ALS and 56 healthy control subjects.

29 patients with Alzheimer's disease and three healthy control subjects.

30 areas were greater in stroke survivors than healthy control subjects.

31 s from 20 infants with CF and 45 age-matched healthy control subjects.

32 NAWM in subjects with MS and white matter in healthy control subjects.

33 hus being less tolerized than BND cells from healthy control subjects.

34 etic subjects and seven age- and BMI-matched healthy control subjects.

35 ptides was significantly higher than that of healthy control subjects.

36 om patients with CF, asthmatic patients, and healthy control subjects.

37 no follow-up; 100 subjects with SCD; and 26 healthy control subjects.

38 ed on their connectivity to the epicentre in healthy control subjects.

39 anti-Pneumocystis IgG and IgE compared with healthy control subjects.

40 icantly higher in asthmatic patients than in healthy control subjects.

41 washout slope (P = .002) when compared with healthy control subjects.

42 heart transplant assessment patients and 18 healthy control subjects.

43 disorder; their first-degree relatives; and healthy control subjects.

44 MR findings in these patients with those in healthy control subjects.

45 both those reporting appetite decreases and healthy control subjects.

46 pression who had not received surgery and 59 healthy control subjects.

47 studies in the patients, family members, and healthy control subjects.

48 from 98 subjects with peanut allergy and 14 healthy control subjects.

49 te allergens in DOCK8-deficient patients and healthy control subjects.

50 s of depressive or anxiety disorders and 644 healthy control subjects.

51 milar to coherence-related activity in V1 of healthy control subjects.

52 ve relapsing-remitting MS in comparison with healthy control subjects.

53 ere elevated modestly compared with those of healthy control subjects.

54 tients with recent-onset type 1 diabetes and healthy control subjects.

55 ubjects who did not convert to psychosis and healthy control subjects.

56 onfirmed CVID in comparison with age-matched healthy control subjects.

57 as a higher prevalence of LGE compared with healthy control subjects.

58 to a greater extent in rMDD individuals than healthy control subjects.

59 ients with mild asthma (asthmatic cases) and healthy control subjects.

60 lung disease control patients without CF and healthy control subjects.

61 ween PD patients off and on medications, and healthy control subjects.

62 very rapid regulatory activation observed in healthy control subjects.

63 CGD compared with those seen in age-matched healthy control subjects.

64 subfields differ between clinical groups and healthy control subjects.

65 ld, respectively, compared with that seen in healthy control subjects.

66 (n = 34), and an equal number of age-matched healthy control subjects.

67 ng with a probabilistic CST constructed from healthy control subjects.

68 EEG was compared from 15 PD patients and 16 healthy control subjects.

69 ts with mild asthma or COPD but not those of healthy control subjects.

70 r frequency of circulating TFR compared with healthy control subjects.

71 striatum in 13 pathological gamblers and 15 healthy control subjects.

72 from patients with mild-to-severe asthma and healthy control subjects.

73 urological memory-disordered patients and 14 healthy control subjects.

74 splay methylation levels similar to those of healthy control subjects.

75 e loop in chronic schizophrenia patients and healthy control subjects.

76 unced evidence of inflammation compared with healthy control subjects.

77 26 with bipolar disorder) and 50 age-matched healthy control subjects.

78 re strongly connected to one another than in healthy control subjects.

79 sample of 20 patients with IS and 20 matched healthy control subjects.

80 did not differ between patients with FEP and healthy control subjects.

81 as not significantly different compared with healthy control subjects.

82 al temporal pole were found in NTSCUs versus healthy control subjects.

83 g of serotonin transporter (SERT) density in healthy control subjects.

84 ated, mild-to-moderate disease compared with healthy control subjects.

85 study of 87 participants with morphea and 26 healthy control subjects.

86 y had metabolic profiles similar to those of healthy control subjects.

87 ed and miglustat treated), heterozygote, and healthy control subjects.

88 nts (at 12-month intervals) from 147 UHR and healthy control subjects.

89 eased in pathological gamblers compared with healthy control subjects.

90 stic fibrosis patients compared with that of healthy control subjects.

91 CD55 was seen less in patients compared with healthy control subjects.

92 of at least moderate severity and 13 matched healthy control subjects.

93 ral blood of allergic asthmatic patients and healthy control subjects.

94 ter in patients with prostate cancer than in healthy control subjects.

95 ents with Gram-negative sepsis compared with healthy control subjects.

96 -free nonsmoking patients with asthma and 10 healthy control subjects.

97 mmatory cells in severe asthma compared with healthy control subjects.

98 f severe child abuse, and of psychiatrically healthy control subjects.

99 with Sacin-high asthma compared with that in healthy control subjects (0.024 vs 0.017, P < .05).

100 artile range [IQR], 0.25-0.96) compared with healthy control subjects (1.8%; IQR, 1.4-2.5; P = 0.001)

101 ge, 22 years) and 36 normotensive previously healthy control subjects (14 men; median age, 43 years;

102 nificantly thinner in glaucoma patients than healthy control subjects (141.7 +/- 66.3 mum vs 155.7 +/

103 ith those in patients with venom allergy and healthy control subjects (21 and 23.4 cells/muL, P < .00

104 1.3% +/- 2.8 vs 28.2% +/- 3.4, P = .030) and healthy control subjects (27.0% +/- 3.1, P = .003).

105 In 126 adults (33 healthy control subjects, 31 patients with mild asthma,

106 rare but more common in pNF subjects than in healthy control subjects (4 versus 1).

107 teroids (0.73%; IQR, 0.46-1.3) compared with healthy control subjects (4.0%; IQR, 1.6-5.0; P = 0.02).

108 tres are included in the analyses here (1233 healthy control subjects, 40-84 years old).

109 Sixty healthy control subjects, 45 unmedicated currently depre

110 COPD (62.7% [SD, 2.3]) compared with that in healthy control subjects (60.3% [SD, 2.2], P < .001).

111 of patients with idiopathic anaphylaxis and healthy control subjects (7 of each) were screened for I

112 simple steatosis, 61.0 sec(-1) +/- 17.3; and healthy control subjects, 72.2 sec(-1) +/- 22.0; P = .00

113 ior cingulate cortex of 289 individuals: 184 healthy control subjects, 83 treated patients with psych

114 chial epithelial cells (pBECs) from COPD and healthy control subjects, a mouse model of cigarette smo

115 r had consistently shorter LTL compared with healthy control subjects across baseline and at the 6-ye

116 oduced significantly more IL-6 compared with healthy control subjects after exposure to toll-like rec

117 Fourteen healthy control subjects also were studied.

118 The first included 93% of healthy control subjects and 100% of asymptomatic RV+ su

119 We recruited 80 healthy control subjects and AD patients with and withou

120 atment-seeking cocaine users (NTSCUs) and 67 healthy control subjects and an independent treatment-co

121 MCs were isolated from patients with PAH and healthy control subjects and assessed for expression of

122 ed in patients with CF compared with that in healthy control subjects and asthmatic patients.

123 Genomic scores of healthy control subjects and asymptomatic RV+ children w

124 ee-digit) to moderate (six-digit) demands in healthy control subjects and consumers with schizophreni

125 hippocampus of patients with MS relative to healthy control subjects and examined the correlations b

126 patients with cerebral amyloid angiopathy to healthy control subjects and examined the relationship b

127 ents with neurodegenerative disease and 4351 healthy control subjects and found p.A152T associated wi

128 ated plasma exosomes from 23 patients and 11 healthy control subjects and found significantly higher

129 No significant difference was found between healthy control subjects and glaucoma patients in the me

130 (27.9%), and these subjects were older than healthy control subjects and had higher triglycerides, l

131 FA maps were obtained in 22 healthy control subjects and in 20 control patients with

132 iabetes with IAH but remained stable in both healthy control subjects and in patients with NAH.

133 matter is diffusely increased compared with healthy control subjects and is further increased in tho

134 icantly reduced in MS patients compared with healthy control subjects and other inflammatory neurolog

135 Both healthy control subjects and patients with Alzheimer's d

136 e differentiation and monocyte activation in healthy control subjects and patients with autoinflammat

137 of injury-induced fibrosis, and in plasma of healthy control subjects and patients with ILD (n = 42 i

138 5b-5p, and miR-143-3p differentiated between healthy control subjects and patients with IS with an ar

139 Serum samples from healthy control subjects and patients with mastocytosis

140 th painful diabetic neuropathy compared with healthy control subjects and patients with painless diab

141 n three independent cohorts, which comprised healthy control subjects and patients with pancreatic ca

142 differentiate patients with PD and MCI from healthy control subjects and patients with PD without MC

143 ed with colors associated with low reward in healthy control subjects and patients with prefrontal da

144 on emission tomography and [(11)C]CURB in 22 healthy control subjects and ten chronic cannabis users

145 uron (LMN)-predominant disease compared with healthy control subjects and those with classic amyotrop

146 ects with atopy but no asthma, and nonatopic healthy control subjects and to determine relationships

147 sal DP2 expression in asthmatic patients and healthy control subjects and to explore its functional r

148 omes from 15 patients with sarcoidosis and 5 healthy control subjects and verified the most interesti

149 nts with severe asthma compared with that in healthy control subjects and was highest in patients wit

150 Compared with both healthy control subjects and youths who had desisted fro

151 om-up') were compared across groups (BDD/MDD/healthy control subjects) and conditions (win/loss antic

152 gram [GSK-HiTDiP] study (113 patients and 57 healthy control subjects) and the Janssen-Brain Resource

153 ols), replication (200 patients with IS, 100 healthy control subjects), and in 72 patients with trans

154 To this end, 40 MS patients, 30 healthy control subjects, and 30 patients with other inf

155 zophrenia or schizoaffective disorder and 50 healthy control subjects, and consumers were divided int

156 relatives who progress to T1D compared with healthy control subjects, and in the CD8(+) T cells in t

157 We compare these data to a set of healthy control subjects, and to a set of patients with

158 with levels in their unaffected siblings and healthy control subjects, and to assess the effects of a

159 Nasal secretions were collected from healthy control subjects, AR patients, and idiopathic rh

160 to 6 times higher in patients with AD versus healthy control subjects at 3 months of age (odds ratio,

161 tified 27 children with atopic wheeze and 70 healthy control subjects at 5 years of age.

162 y had a significantly lower PCr/ATP than did healthy control subjects at 7 T (1.54 +/- 0.39 vs 1.95 +

163 ating patients with Alzheimer's disease from healthy control subjects based on visual images or the r

164 s administered to 11 patients with MS and 22 healthy control subjects before scanning with positron e

165 ith Trail-Making Test, Part B, time spent in healthy control subjects but not in chronic schizophreni

166 triatum predicted worse cognitive control in healthy control subjects but not in chronic schizophreni

167 generated symptoms in patients with NAH and healthy control subjects but not in patients with IAH.

168 kedly increased in psoriatic patients versus healthy control subjects, but there was no statistically

169 striatal and fronto-parietal connectivity in healthy control subjects, by bottom-up striatal-frontal

170 (P = 0.05) and IL-12p40 levels (P = 0.04) in healthy control subjects carrying the TT genotype.

171 In duodenal biopsy specimens of healthy control subjects, CD4(+) T cells were determined

172 uptake per volume of BAT compared with young healthy control subjects, cold-induced oxidative metabol

173 nically diagnosed Parkinson's disease and 26 healthy control subjects completed a saccadic Go/No-Go t

174 ts with first-episode psychosis (FEP) and 18 healthy control subjects completed the study.

175 fferences between vulnerable individuals and healthy control subjects could help identify those at hi

176 e collected from 20 patients with OCD and 22 healthy control subjects during a flanker task.

177 Compared with healthy control subjects, epilepsy patients tended to ex

178 While healthy control subjects exploited the anticorrelated st

179 134 patients with Hymenoptera allergy and 76 healthy control subjects for comparison.

180 patients with relapsing-remitting MS and 32 healthy control subjects from four centers underwent str

181 data and biospecimens from 909 AA and 847 EA healthy control subjects from the Carolina Breast Cancer

182 ood leukocytes from 105 subjects with VL and healthy control subjects from the endemic region of Muza

183 er, 293 patients with schizophrenia, and 330 healthy control subjects genome-wide with the Illumina H

184 ubjects had 11C-Pittsburgh compound B and 10 healthy control subjects had 11C-(R)-PK11195 positron em

185 Twelve age-matched healthy control subjects had 11C-Pittsburgh compound B a

186 Medication-free patients with MDD and healthy control subjects (HC) completed baseline rs-fcMR

187 in a total of 281 patients with BPD and 293 healthy control subjects (HC) were included.

188 high familial risk of mood disorders and 93 healthy control subjects (HC).

189 ources more intensely but more narrowly than healthy control subjects (HCS).

190 without polyneuropathy (nDPN)-along with 30 healthy control subjects (HCs).

191 free) were compared with 18 age-matched male healthy control subjects (HCs).

192 ources more narrowly but more intensely than healthy control subjects (HCS).

193 ubjects with schizophrenia (SCH) relative to healthy control subjects (HCs).

194 urately differentiate patients with MDD from healthy control subjects (HCs).

195 oid-naive 4- to 15-year-old German children (healthy control subjects [HCs], patients with AA, and pa

196 ated by APS-IgG and SLE/APS- IgG compared to healthy control subjects' IgG, and FXa alone.

197 encing was performed for all index cases and healthy control subjects in a central laboratory.

198 sease did not show differences compared with healthy control subjects in cortical thickness and diffu

199 rent depression differed from each other and healthy control subjects in density of connections, conn

200 difference between pathological gamblers and healthy control subjects in terms of dopamine transmissi

201 expression from 155 subjects with asthma and healthy control subjects in the Severe Asthma Research P

202 endent humans as identified by DSM-IV and 15 healthy control subjects matched for age, sex, and smoki

203 cating that tetramer-binding memory cells in healthy control subjects may be cross-reactive T cells.

204 d with patients who had simple steatosis and healthy control subjects (mean +/- standard deviation fo

205 er instability were investigated in 33 young healthy control subjects (mean age +/- standard deviatio

206 atients with T1D and 42 age- and sex-matched healthy control subjects (mean age 12.7 years, 50% males

207 andard deviation, 34.6 years +/- 9.5) and 10 healthy control subjects (mean age, 31.5 years +/- 4.4)

208 tandard deviation, 31 years +/- 5), 34 older healthy control subjects (mean age, 67 years +/- 8), 34

209 lated in patients with IS compared with both healthy control subjects (miR-125a-5p [1.8-fold; P=1.5x1

210 AO-A VT compared with moderate BPD, MDE, and healthy control subjects (multivariate analysis of varia

211 The calf was imaged at 3-T in young healthy control subjects (n = 12), age-matched control s

212 rnative idiopathic ILDs (a-ILD; n = 41), and healthy control subjects (n = 127).

213 depressive episode (MDE) only (n = 14), and healthy control subjects (n = 14).

214 sognosia (n = 15), as well as neurologically healthy control subjects (n = 15).

215 n patients with ILD, patients with COPD, and healthy control subjects (n = 16 each) during incrementa

216 n, and compared their performance to matched healthy control subjects (n = 18), in behavioural tasks

217 sed in subjects with severe PAR (n = 46) and healthy control subjects (n = 19).

218 th generalized anxiety disorder (n = 24) and healthy control subjects (n = 20), patients with post-tr

219 th pathological anxiety (n = 25) and matched healthy control subjects (n = 23) completed a gambling t

220 ders without CU traits (CD/CU-; n = 25), and healthy control subjects (n = 24).

221 (T1D, n = 16) and compared them to levels in healthy control subjects (n = 27).

222 ith persistent atopic asthma (n = 36) versus healthy control subjects (n = 36).

223 nd classified into four clinical groups: RV- healthy control subjects (n = 37), RV+ asymptomatic subj

224 ted (n = 21) patients with schizophrenia and healthy control subjects (n = 45) performed the self-ord

225 ent (n = 1062) or remitted (n = 711) MDD and healthy control subjects (n = 497).

226 surgically cured pheochromocytoma (n = 31), healthy control subjects (n = 51), and hypertensive cont

227 les from either patients with GP (n = 14) or healthy control subjects (n = 6) were cocultured ex vivo

228 ewly diagnosed type 1 diabetes (n = 654) and healthy control subjects (n = 605) were analyzed in radi

229 h normal awareness of hypoglycemia (NAH) and healthy control subjects (n = 7 per group).

230 ts with severe asthma and previously studied healthy control subjects (n = 7) and patients with mild-

231 hepatic steatosis without NASH (n = 11), and healthy control subjects (n = 9).

232 ith idiopathic or heritable PAH (n=365) from healthy control subjects (n=121) after correction for mu

233 ofile (n=38), MCI with AD profile (n=20) and healthy control subjects (n=20).

234 child abuse, as well as from psychiatrically healthy control subjects (N=26).

235 lammatory response in monocytes derived from healthy control subjects (n=6).

236 hizophrenia, N=51; psychosis risk, N=39; and healthy control subjects, N=53), the authors conducted a

237 ts without DPN (eight men, 12 women), and 20 healthy control subjects (nine men, 11 women).

238 n patients with mitral regurgitation than in healthy control subjects (P < .001).

239 diabetic patients without DPN (P < .001) and healthy control subjects (P < .001).

240 d with both patients without suicidality and healthy control subjects (p < .05 for each).

241 re significantly higher in PAR compared with healthy control subjects (P < 0.0001).

242 ass index was increased in HTN compared with healthy control subjects (p < 0.05), but not in the 2 ph

243 PBR111 distribution volume ratio relative to healthy control subjects (p = .024), and the hippocampal

244 Relative to healthy control subjects, pathologically anxious partici

245 RT-PCR and compared them with specimens from healthy control subjects, patients with atopic dermatiti

246 (P < .001) in patients with HSP relative to healthy control subjects, regardless of their clinical p

247 Depressed individuals versus healthy control subjects, show increased expectation of

248 nal vein equivalent was 195.5 +/- 9.91 MU in healthy control subjects, significantly different from b

249 We demonstrated in healthy control subjects that diffusion basis spectrum i

250 10 totally pancreatectomized patients and 10 healthy control subjects to a 75-g oral glucose toleranc

251 e patients with Alzheimer's disease and five healthy control subjects to analyse the presence of phos

252 with schizophrenia are more vulnerable than healthy control subjects to the acute behavioral and cog

253 Study 1, 19 methamphetamine-dependent and 26 healthy control subjects underwent [(18)F]fallypride pos

254 patients with relapsing-remitting MS and 20 healthy control subjects underwent a 3-T resting-state f

255 Forty-four patients with epilepsy and 16 healthy control subjects underwent an electroencephalogr

256 patients with relapsing-remitting MS and six healthy control subjects underwent diffusion-weighted im

257 halitis after the acute disease stage and 25 healthy control subjects underwent multimodal structural

258 , 8 steroid-naive subjects with COPD, and 21 healthy control subjects underwent phlebotomy, sputum in

259 ts with newly diagnosed, untreated MM and 16 healthy control subjects underwent spinal MR imaging inc

260 even patients with asthma and 17 age-matched healthy control subjects underwent spirometry, body plet

261 Patients with stable asthma and healthy control subjects underwent spirometry, methachol

262 Relative to healthy control subjects, unmedicated adolescents with M

263 enia/schizoaffective patients relative to 42 healthy control subjects using a fixed reference tone au

264 with major depressive disorder (MDD) versus healthy control subjects using graph theory methods.

265 isorder or bipolar disorder in comparison to healthy control subjects using two separate, consecutive

266 ood from patients with atopic dermatitis and healthy control subjects was analyzed with flow cytometr

267 Reduced cortical glutamine relative to healthy control subjects was observed in patients with s

268 ith PD (54 with MCI, 116 without MCI) and 41 healthy control subjects was obtained by using determini

269 (NSAID-LTP-A), 7 patients with LTP-A, and 13 healthy control subjects was performed to identify disti

270 mean eGFR =37.6 ml/min per 1.73 m(2)) and 39 healthy control subjects, we quantified insulin sensitiv

271 Eleven subjects with type 2 diabetes and a healthy control subject were recruited with the approval

272 Healthy control subjects were also evaluated in this stu

273 NAWM in subjects with MS and white matter in healthy control subjects were assessed by using the Mann

274 2D (HbA1c >7.5%) and 24 age- and sex-matched healthy control subjects were consecutively enrolled.

275 st differentially expressed in asthma versus healthy control subjects were enriched among genes assoc

276 a confirmed diagnosis of CF and age-matched healthy control subjects were enrolled at three North Am

277 21 IGE patients with absence seizures and 24 healthy control subjects were enrolled.

278 e functional connectivity between NTSCUs and healthy control subjects were identified.

279 images from 453 patients with NIDCM and 150 healthy control subjects were included between 2005 and

280 48 patients with Parkinson's disease and 23 healthy control subjects were included in this study.

281 21 subjects with atopy but no asthma, and 21 healthy control subjects were profiled by using 16S rRNA

282 h bilateral PVNH and 14 age- and sex-matched healthy control subjects were prospectively acquired by

283 Twenty-eight patients with CSM and 10 healthy control subjects were prospectively recruited an

284 Fifteen healthy control subjects were studied at three equivalen

285 Healthy control subjects were studied under normoglycemi

286 imer's disease and 16 (age- and sex-matched) healthy control subjects were studied using Actiheart de

287 n = 9), mild asthma patients (n = 7), and 10 healthy control subjects were studied.

288 pe 2 diabetes and 29 age- and weight-matched healthy control subjects were treated in randomized orde

289 Sera of 1062 patients with CSU and 482 healthy control subjects were used in an IgE-anti-IL-24-

290 a cohort of 58 immunodeficiency patients and healthy control subjects were used to probe microarrays.

291 ry reserve capacity compared with those from healthy control subjects, whereas mitochondrial reactive

292 nts with increased or decreased appetite and healthy control subjects while viewing photographs of fo

293 ith adrenomyeloneuropathy and 12 age-matched healthy control subjects who underwent quantitative magn

294 rst-episode psychosis as well as age-matched healthy control subjects with magnetic resonance spectro

295 ctobacillus and Staphylococcus compared with healthy control subjects with no family history of autoi

296 e mutations and were compared with images in healthy control subjects with no family history of breas

297 Compared with the healthy controls, subjects with MetS had significantly r

298 Compared with healthy controls, subjects with TLE demonstrated patholo

299 .1 [95% CI, 37.5-40.9], respectively) and 30 healthy control subjects without AD were analyzed for 14

300 S patients without encephalopathy, and to 15 healthy control subjects without CMS.